GenScript’s SARS-CoV-2 Neutralizing Antibody Detection Kit uses novel technology to detect antibodies specific to the spike protein receptor binding domain (S-RBD) of the SARS-CoV-2 virus responsible for COVID-19. Antibodies to this specific antigen are generated by the body via two methods 1) natural infection or 2) vaccination. The S-RBD is the critical viral component used by the virus to enter human cells and is the primary target used in vaccine development to elicit a specific immune response. Detecting the presence of the neutralizing antibodies is the first step in determining whether there is an adaptive immune response!
Placing An Order
SARS-CoV-2 Neutralizing Antibody Detection Kit
The neutralizing antibody test uses novel technology to detect antibodies specific to the spike receptor binding domain (S-RBD). Antibodies to this specific antigen are generated by the body by either natural infection or vaccination as the S-RBD is the critical viral component used by the virus to enter human cells and is the primary target used in vaccine development.
Specifications
- Each kit provides the necessary materials for the test, including:
- Individually packaged test cards
- Sample buffer
- Lancet device
- Capillary collection tube
- Alcohol pad
- This test provides a Qualitative result.
- Sample type: Blood, serum or plasma by venous collection or fingerprick blood sample
- Store at 4-30°C until use
- 18 month shelf life
Recommended usage
- This test does not diagnose a SARS-CoV-2 infection.
- The CE-IVD at-home authorization is a non-prescription EU authorization that allows individuals to evaluate their immune response to COVID-19 vaccination or infection in a home-based setting.
- The test is also offered in a Research Use Only format, where applicable, and is not to be used in diagnostic procedures.
Less invasive method to monitor patient recovery
Results in 15 minutes
Multiple use scenarios including immune passport, workplace testing, and individual vaccine efficacy evaluation
Includes colorimetric card for enhanced qualitative interpretation
Samples from a cohort of patients were tested using the SARS-CoV-2 Neutralizing Antibody Rapid Test Kit. The combined cohort consisted of samples from normal healthy people (n= 25) and samples from confirmed SARS-CoV-2 positive patients (n=25) based on plaque reduction neutralization test (PRNT) results.
| Plaque Reduction Neutralization Test (PRNT) | |||
|---|---|---|---|
| SARS-CoV-2 Neutralizing Antibody Rapid Test Kit |
Positive | 25 | 1 |
| Negative | 0 | 24 | |
| Sensitivity | 100% (95% CI 86.7-100%) |
||
| Specificity | 96.0% (95% CI 80.5-99.3%) |
||
